Literature DB >> 6861123

Demonstration of immunogenicity with the poorly immunogenic B16 melanoma.

C Celik, D A Lewis, M H Goldrosen.   

Abstract

Animal tumors of spontaneous origin have consistently been found to be less immunogenic than are tumors induced by chemical carcinogens or oncogenic viruses. Spontaneous tumors rarely demonstrate significant immunogenicity in classical transplantation rejection tests. This study demonstrates a novel approach to the question of tumor immunogenicity using viable tumor cells in diffusion chambers. Classical transplantation rejection was induced to the poorly immunogenic, spontaneous B16 murine melanoma by implantation of diffusion chambers containing viable B16 melanoma tumor cells. Implantation of B16 chambers i.p. for at least 4 weeks induced specific, long-term resistance to subsequent live B16 tumor cell challenge. In contrast, immunization with irradiated tumor cells for the same time interval resulted in a delay of tumor growth but had no effect on survival. These studies demonstrate the possibility that a significant anti-tumor immune response against the B16 melanoma may be induced without the presence and negative regulatory influences of a progressively growing B16 tumor. In addition, the diffusion chamber sensitization technique may detect the antigenicity of some tumors which are not detectable by classical transplantation rejection tests. Thus, the diffusion chamber technique provides another avenue for testing the immunogenicity of tumors, especially those of spontaneous origin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861123

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor.

Authors:  Adam T Waickman; Angela Alme; Liana Senaldi; Paul E Zarek; Maureen Horton; Jonathan D Powell
Journal:  Cancer Immunol Immunother       Date:  2011-11-25       Impact factor: 6.968

2.  Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap.

Authors:  Wantong Song; Limei Shen; Ying Wang; Qi Liu; Tyler J Goodwin; Jingjing Li; Olekasandra Dorosheva; Tianzhou Liu; Rihe Liu; Leaf Huang
Journal:  Nat Commun       Date:  2018-06-08       Impact factor: 14.919

3.  Yap suppresses T-cell function and infiltration in the tumor microenvironment.

Authors:  Eleni Stampouloglou; Nan Cheng; Anthony Federico; Emily Slaby; Stefano Monti; Gregory L Szeto; Xaralabos Varelas
Journal:  PLoS Biol       Date:  2020-01-13       Impact factor: 8.029

4.  Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors.

Authors:  T Suzuki; H Tahara; S Narula; K W Moore; P D Robbins; M T Lotze
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

5.  New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.

Authors:  Alessandra Lopes; Chiara Bastiancich; Mathilde Bausart; Sophie Ligot; Laure Lambricht; Kevin Vanvarenberg; Bernard Ucakar; Bernard Gallez; Véronique Préat; Gaëlle Vandermeulen
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.